Spectris shareholders will receive £40.00 per share, including all declared dividends—representing a 6.3% premium over Advent's previously announced £37.63 per share offer. KKR's proposal values Spectris' equity at £4.1 billion, up from the £3.8 billion under Advent's terms.
Following KKR's formal bid, Spectris' board unanimously withdrew its prior recommendation of Advent's offer and endorsed the superior proposal from KKR. The move followed weeks of competitive engagement, during which Spectris had rejected two earlier proposals from KKR, including one submitted on June 13.
Regulatory Hurdles and Timeline
The acquisition is expected to proceed via a court-sanctioned scheme of arrangement, similar to the initial Advent transaction structure, and remains subject to shareholder and regulatory approval. If approved, completion is expected in early 2026.
The bidding war has underscored growing foreign interest in undervalued British assets. Spectris, listed on the FTSE 250, had been trading at a notable discount to its U.S. peers despite a series of value-enhancing moves, including strategic acquisitions and cost-cutting programs.
Background: Advent's Bid and Competitive Dynamics
On June 23, Spectris had agreed to a £4.4 billion deal with Advent International, which included a £37.35 cash consideration per share and a 28 pence interim dividend. At the time, the offer represented an 85% premium to the company's share price on June 6—just before Advent's approach became public.
Spectris had stated that its board “unanimously intended to recommend” the Advent proposal. However, KKR, which had made its initial approach on June 2, continued advancing due diligence and financing arrangements, signaling intent to deliver a more competitive bid.
KKR had until July 11 under UK Takeover Panel rules to make a formal offer—an opportunity it seized just ahead of that deadline.
Strong Business Fundamentals Remain
Founded in London, Spectris delivers precision instrumentation, software, and test equipment across a variety of industries, including pharmaceuticals, steel, and automotive. Operating in 36 countries, the company completed several acquisitions in 2024—Micromeritics and SciAps—which are expected to significantly boost profit in 2025.
Despite a 3.4% year-over-year decline in Q1 2025 revenues, the company ended the quarter with a strong order book of £529 million, up 4% in constant currency terms. Cost savings from its Profit Improvement Programme are forecast to deliver £30 million in 2025, reaching a £50 million annual run-rate by 2026.
CEO Andrew Heath reaffirmed that the combination of savings and acquisition synergies could yield over £60 million in incremental profit during 2025, underscoring the company's value potential and strategic appeal to bidders.
With its enhanced offer, KKR has not only secured the acquisition of one of the UK's most attractive industrial assets but also underscored the continuing pressure on London's public markets, which have seen a steady exodus of firms amid foreign takeovers and low IPO activity.
As the transaction progresses through approvals, attention will turn to how KKR plans to steer Spectris' long-term growth—amid global economic uncertainty and mounting trade pressures.
